LXEO - Lexeo Therapeutics, Common Stock - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

LXEO is currently covered by 4 analysts with an average price target of $19.37. This is a potential upside of $15.11 (354.69%) from yesterday's end of day stock price of $4.26.

Lexeo Therapeutics, Common Stock's activity chart (see below) currently has 0 price targets and 16 ratings on display. The stock rating distribution of LXEO is 100% BUY.

Stock Analyst Price Targets - Review

Highest price target for LXEO is $24, Lowest price target is $19, average price target is $22.25.

Most recent stock forecast was given by LUCA ISSI from RBC on 21-Jan-2025. First documented stock forecast 28-Nov-2023.

Best performing analysts who are covering LXEO - Lexeo Therapeutics, Common Stock:

Mitchell Kapoor Geulah Livshits Luca Issi Mani Foroohar

Currently out of the existing stock ratings of LXEO, 16 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$24

$19.53 (436.91%)

$24

5 months 27 days ago
(21-Jan-2025)

0/4 (0%)

$19.12 (391.80%)

Buy

$23

$18.53 (414.54%)

$21

8 months 4 days ago
(14-Nov-2024)

0/5 (0%)

$15.22 (195.63%)

Buy

$19

$14.53 (325.06%)

$20

8 months 5 days ago
(13-Nov-2024)

0/3 (0%)

$11.36 (148.69%)

Buy

$23

$18.53 (414.54%)

$23

8 months 18 days ago
(30-Oct-2024)

0/4 (0%)

$14.72 (177.78%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is LXEO (Lexeo Therapeutics, Common Stock) average time for price targets to be met?

On average it took 0 days on average for the stock forecasts to be realized with a an average price target met ratio 0

Which analyst has the current highest performing score on LXEO (Lexeo Therapeutics, Common Stock) with a proven track record?

MITCHELL KAPOOR

Which analyst has the current lower performing score on LXEO (Lexeo Therapeutics, Common Stock) with a proven track record?

MANI FOROOHAR

Which analyst has the most public recommendations on LXEO (Lexeo Therapeutics, Common Stock)?

Mitchell Kapoor has 12 price targets and 8 ratings on LXEO

Which analyst is the currently most bullish on LXEO (Lexeo Therapeutics, Common Stock)?

Luca Issi with highest potential upside - $19.53

Which analyst is the currently most reserved on LXEO (Lexeo Therapeutics, Common Stock)?

Mani Foroohar with lowest potential downside - $14.53

Lexeo Therapeutics, Common Stock in the News

Stifel reiterates Buy rating on Lexeo Therapeutics stock at $21 price target

Investing.com – Stifel has reiterated its Buy rating and $21.00 price target on Lexeo Therapeutics (NASDAQ:LXEO), currently trading at $4.45, following the company’s announcement of Breakthrough Therapy Designation for its LX2006 treatment. Analyst consensus remains strongly bullish with targets ranging from $10 to $28, according to InvestingPro data. The Breakthrough Therapy Designation was granted for...

Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia

Breakthrough Therapy designation based on interim clinical data from Phase I/II trials showing clinically meaningful improvements in cardiac biomarkers and functional measures LX2006 also selected for FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) program, created to facilitate CMC registrational readiness and support faster patient access NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) —...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?